{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:07:37Z","timestamp":1769839657033,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012781","name":"MSD K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen Pharmaceutical K.K."},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nippon Chemiphar"},{"name":"Phizer"},{"DOI":"10.13039\/501100004820","name":"Mochida Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004820","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yoshitomiyakuhin"},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12888-019-2181-9","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T14:02:33Z","timestamp":1561557753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term mood\/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression"],"prefix":"10.1186","volume":"19","author":[{"given":"Shigenobu","family":"Kanba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsukuni","family":"Murasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Arita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Kuroishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,26]]},"reference":[{"key":"2181_CR1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Bipolar and related disorders. In: Diagnostic and statistical manual of mental disorders. 5th ed; 2013.","edition":"5"},{"issue":"3","key":"2181_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archgenpsychiatry.2011.12","volume":"68","author":"KR Merikangas","year":"2011","unstructured":"Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241\u201351.","journal-title":"Arch Gen Psychiatry"},{"key":"2181_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/0269881116636545","volume":"30","author":"GM Goodwin","year":"2016","unstructured":"Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, Coghill DR, Fazel S, Geddes JR, Grunze H, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30:495\u2013553.","journal-title":"J Psychopharmacol"},{"key":"2181_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3109\/15622970903555881","volume":"11","author":"H Grunze","year":"2010","unstructured":"Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, M\u00f6ller HJ, Kasper S. WFSBP task force on treatment guidelines for bipolar disorders. The world Federation of Societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11:81\u2013109.","journal-title":"World J Biol Psychiatry."},{"key":"2181_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/pcn.12060","volume":"67","author":"S Kanba","year":"2013","unstructured":"Kanba S, Kato T, Terao T, Yamada K. Committee for Treatment Guidelines of mood disorders. JSoMD guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012. Psychiatry Clin Neurosci. 2013;67:285\u2013300.","journal-title":"Psychiatry Clin Neurosci"},{"key":"2181_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bdi.12025","volume":"15","author":"LN Yatham","year":"2013","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, Macqueen G, McIntyre RS, Sharma V, et al. Canadian network for mood and anxiety treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15:1\u201344.","journal-title":"Bipolar Disord"},{"issue":"7","key":"2181_CR7","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","volume":"162","author":"JR Calabrese","year":"2005","unstructured":"Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351\u201360.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"2181_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","volume":"26","author":"ME Thase","year":"2006","unstructured":"Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR, Group BIS. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"1\u20132","key":"2181_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jad.2009.10.007","volume":"121","author":"T Suppes","year":"2010","unstructured":"Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010;121(1\u20132):106\u201315.","journal-title":"J Affect Disord"},{"issue":"10","key":"2181_CR10","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1007\/s00213-018-4977-6","volume":"235","author":"M Murasaki","year":"2018","unstructured":"Murasaki M, Koyama T, Kanba S, Takeuchi M, Shimizu Y, Arita E, Kuroishi K, Takeuchi M, Kamei S. Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression. Psychopharmacology. 2018;235(10):2859\u201369.","journal-title":"Psychopharmacology."},{"issue":"3","key":"2181_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/archpsyc.60.3.261","volume":"60","author":"LL Judd","year":"2003","unstructured":"Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, Solomon DA, Leon AC, Keller MB. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60(3):261\u20139.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"2181_CR12","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","volume":"59","author":"LL Judd","year":"2002","unstructured":"Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530\u20137.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"2181_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3109\/15622975.2012.665177","volume":"15","author":"AH Young","year":"2014","unstructured":"Young AH, McElroy SL, Olausson B, Paulsson B, Embolden I. Embolden II investigators. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J Biol Psychiatry. 2014;15(2):96\u2013112.","journal-title":"World J Biol Psychiatry"},{"key":"2181_CR14","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: American Psychiatric Association Publishing; 2000."},{"issue":"3","key":"2181_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0165-1781(97)00123-6","volume":"73","author":"MK Spearing","year":"1997","unstructured":"Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the clinical global impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159\u201371.","journal-title":"Psychiatry Res"},{"key":"2181_CR16","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: the extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions\u2014E1. \n                    http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E1\/Step4\/E1_Guideline.pdf\n                    \n                   (Accessed June 19, 2018)."},{"issue":"2","key":"2181_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4088\/JCP.08m04942gre","volume":"71","author":"SL McElroy","year":"2010","unstructured":"McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163\u201374.","journal-title":"J Clin Psychiatry."},{"issue":"2","key":"2181_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4088\/JCP.08m04995gre","volume":"71","author":"AH Young","year":"2010","unstructured":"Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M, Investigators EI. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010;71(2):150\u201362.","journal-title":"J Clin Psychiatry"},{"key":"2181_CR19","doi-asserted-by":"publisher","unstructured":"Nashed MG, Restivo MR, Taylor VH. Olanzapine-induced weight gain in patients with Bipolar I Disorder: A meta-Analysis. Prim Care Companion CNS Disord. 2011;13(6). \n                    https:\/\/doi.org\/10.4088\/PCC.11r01174\n                    \n                  .","DOI":"10.4088\/PCC.11r01174"},{"issue":"9","key":"2181_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2165\/11634500-000000000-00000","volume":"26","author":"M De Hert","year":"2012","unstructured":"De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26(9):733\u201359.","journal-title":"CNS Drugs"},{"issue":"2","key":"2181_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/wps.20204","volume":"14","author":"CU Correll","year":"2015","unstructured":"Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119\u201336.","journal-title":"World Psychiatry"},{"key":"2181_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1475-2832-3-7","volume":"3","author":"KD McLaren","year":"2004","unstructured":"McLaren KD, Marangell LB. Special considerations in the treatment of patients with bipolar disorder and medical co-morbidities. Ann Gen Hosp Psychiatry. 2004;3:7.","journal-title":"Ann Gen Hosp Psychiatry"},{"issue":"5","key":"2181_CR23","first-page":"929","volume":"3","author":"D La Torre","year":"2007","unstructured":"La Torre D, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007;3(5):929\u201351.","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"2181_CR24","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/archpsyc.57.6.553","volume":"57","author":"S Kapur","year":"2000","unstructured":"Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia. Arch Gen Psychiatry. 2000;57(6):553\u20139.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"2181_CR25","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S0188-4409(02)00403-4","volume":"33","author":"M Atmaca","year":"2002","unstructured":"Atmaca M, Kuloglu M, Tezcan E, Canatan H, Gecici O. Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Arch Med Res. 2002;33(6):562\u20135.","journal-title":"Arch Med Res"},{"issue":"2","key":"2181_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/JCP.0b013e318166c4d5","volume":"28","author":"K Gao","year":"2008","unstructured":"Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia. J Clin Psychopharmacol. 2008;28(2):203\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"2181_CR27","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","volume":"161","author":"CU Correll","year":"2004","unstructured":"Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414\u201325.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"2181_CR28","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1176\/appi.ajp.2014.13111501","volume":"171","author":"A Viktorin","year":"2014","unstructured":"Viktorin A, Lichtenstein P, Thase ME, Larsson H, Lundholm C, Magnusson PK, Landen M. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry. 2014;171(10):1067\u201373.","journal-title":"Am J Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-019-2181-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-019-2181-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-019-2181-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T23:05:46Z","timestamp":1593039946000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-019-2181-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,26]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2181"],"URL":"https:\/\/doi.org\/10.1186\/s12888-019-2181-9","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,26]]},"assertion":[{"value":"31 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in adherence to the ethical principles that are based on the Declaration of Helsinki, Good Clinical Practice, guidelines of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, and applicable laws and regulations. Patients provided written informed consent prior to commencement of the study. The following institutional review boards provided ethical approval for the study: Hokkaido University Hospital, Kyushu University Hospital, Akita City Hospital, Nanko Psychiatric Institute, Mito Medical Center, Seimou Hospital, Shoda Hospital, Adachi Kyosai Hospital, Nippon Medical School Chiba Hokusoh Hospital, Suzuki Hospital, Neuropsychiatric Research Institute, Showa University Karasuyama Hospital, Suzuki Internal Medicine and Cardiology, Akasaka Clinic, Mizuo Clinic, Himorogi Psychiatric Institute, Keihin-chuo Clinic & Hisamitsu Clinic & Masabayashi Clinic, Tokyo-eki Center-building Clinic, Eda Memorial Hospital, Kayaba-cho Dermatology, Minami-toyama Nakagawa Hospital, Japanese Red Cross Society Azumino Hospital, Aichi Medical Association, Yuge Hospital, Asakayama General Hospital, Kindai University Hospital, Kusatsu Hospital, Tokushima University Hospital, Omuta-chuo Hospital, Haradoi Hospital, Yokohama Minoru Clinic, University of the Ryukyus Hospital, Kurayoshi Hospital, Nishigahara Hospital, Arakaki Hospital, Hannan Hospital, Kagawa University Hospital, Yatsushiro-kousei Hospital, Tokyo Shinjuku Medical Center, Nagoya University Hospital, Oita University Hospital, Okayama University Hospital, Fujita Health University Hospital, Hiroshima University Hospital, Hospital of the University of Occupational and Environmental Health, Ashiribetsu Hospital, Riverside Clinic, Minami Sakai Hospital, Keio University Hospital, Tokyo Musashino Hospital, Mitsui Memorial Hospital, Brain Attack Center Ota Memorial Hospital, Hokkaido Study Group of Clinical Psychopharmacology, Okamoto Hospital, Center Hospital of the National Center for Global Health and Medicine, Ongata Hospital, Yamato Mental Medical Center, Sapporo City General Hospital, Hiro Clinic Omori, Japanese Red Cross Medical Center, Negishi Hospital, Nishi Hospital, and Kondou Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Specific and substantive relationships are as follows: Shigenobu Kanba declares honoraria from MSD K.K., Astellas Pharma Inc., Mochida Pharmaceutical Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., Dainippon-Sumitomo Pharma Co. Ltd., Otsuka Pharmaceutical Co., Ltd., Taisho-Toyama Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Meiji Seika Pharma Co. Ltd., Yoshitomiyakuhin Co., Nippon Chemiphar Co. Ltd., Daiichi Sankyo Co. Ltd., Pfizer Inc., Shionogi & Co., Ltd., and Mitsubishi Tanabe Pharma Co., and research funding from MSD K.K., Dainippon-Sumitomo Pharma Co. Ltd., Janssen Pharmaceutical K.K., Astellas Pharma Inc., Nippon Chemiphar Co. Ltd., Pfizer Inc., Mochida Pharmaceutical Co. Ltd., Eisai Co., Ltd. Meiji Seika Pharma Co., Ltd., Yoshitomiyakuhin Co., Shionogi & Co., Ltd., and Mitsubishi Tanabe Pharma Co. Mitsukuni Murasaki declares personal fees from Astellas Pharma Inc., Meiji Seika Pharma Co., Ltd., Eli Lilly Japan, Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., and Janssen Pharmaceutical K.K. Tsukasa Koyama declares personal fees from Astellas Pharma Inc., Eli Lilly Japan, Otsuka Pharmaceutical, and Mitsubishi Tanabe Pharma Co. Masahiro Takeuchi () declares personal fees from Astellas Pharma Inc. Yuriko Shimizu, Eri Arita, Kentaro Kuroishi, Masahiro Takeuchi, and Shinya Kamei are employees of Astellas Pharma Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"198"}}